

Sequence Range: 1 to 494




FIGURE 1

Sequence Range: 1 to 428

```

      10      20      30      40      50
      *      *      *      *      *
      *      *      *      *      *
TTACTTGACG ACTCGGG ATG GGA TGG AGC TAT ATC ATC TTC TTC TTG GTA TCA
      M      G      W      S      Y      I      I      F      F      L      V      S>

      60      70      80      90      100
      *      *      *      *      *
      *      *      *      *      *
ACA GCT ACA AGT GTC CAC TCC CAG GTC CAA CTG CAG CAG CCT GGG GCT
      T      A      T      S      V      H      S      Q      V      Q      L      Q      Q      P      G      A>

      110      120      130      140
      *      *      *      *
      *      *      *      *
GAG CTT GTG AAG CCT GGG ACT TCA GTG AAG CTG TCC TGC AAG GGT TAT
      E      L      V      K      P      G      T      S      V      K      L      S      C      K      G      Y>

      150      160      170      180      190
      *      *      *      *      *
      *      *      *      *      *
GGC TAC ACC TTC ACC AGC TAC TGG ATG CAC TGG GTG AAG CAG AGG CCT
      G      Y      T      F      T      S      Y      W      M      H      W      V      K      Q      R      P>

      200      210      220      230      240
      *      *      *      *      *
      *      *      *      *      *
GGA CAA GGC CTT GAG TGG ATC GGA GAG ATT GAT CCT TCT GAG AGT AAT
      G      Q      G      L      E      W      I      G      E      I      D      P      S      E      S      N>

      250      260      270      280      290
      *      *      *      *      *
      *      *      *      *      *
ACT AAC TAC AAT CAA AAA TTC AAG GGC AAG GCC ACA TTG ACT GTA GAC
      T      N      Y      N      Q      K      F      K      G      K      A      T      L      T      V      D>

      300      310      320      330      340
      *      *      *      *      *
      *      *      *      *      *
ATT TCC TCC AGC ACA GCC TAC ATG CAG CTC AGC AGC CTG ACA TCT GAG
      I      S      S      S      T      A      Y      M      Q      L      S      S      L      T      S      E>

      350      360      370      380
      *      *      *      *
      *      *      *      *
GAC TCT GCG GTC TAC TAT TGT GCA AGA GGG GGT TAC GAC GGA TGG GAC
      D      S      A      V      Y      Y      C      A      R      G      G      Y      D      G      W      D>

      390      400      410      420
      *      *      *      *
      *      *      *      *
TAT GCT ATT GAC TAC TGG GGT CAA GGC ACA TCA GTC ACC
      Y      A      I      D      Y      W      G      Q      G      T      S      V      T>

```

FIGURE 2

Sequence Range: 1 to 535




FIGURE 3




FIGURE 4A




FIGURE 4B

Percent Identity: 71.429

GM607'CL

1 DVVVVTOTPLSLPVSPFGDQVSISC[RSSQSLAKSYGNTYLS]WYLKPGQSPQ
1 DIVMTQSPFLSLFVTPGEPASISC[RSSQSLLSNGYNYLD]WYLKPGQSPQ
CDR 1. 1

50

50

Act-1.v1

GM607'CL

51 LLIY[GISNRFS]GVPDRFSGSGSGTDFTLKISTIKPEDLGMYYC[LOGTHQP 100
51 LLIY[LGSNRAS]GVPDRFSGSGSGTDFTLKISRVEAEDVGYYC[MOALQTP 100
[CDR 2] [CDR 3

Act-1.v1

GM607'CL

101 YTJFGGGTKLEIK 112
101 QTJFGQGTKVEIK 112

FIGURE 5

Percent Similarity: 82.353

Percent Identity: 68.067




FIGURE 6

1 ATGAAGTTGCCGTGTTAGGCTGTTGGTGCTTCTGTTGTTCTGGATTCTGTTTCCGGAGGT 60
 TACTTCAACGGACAATCCGACAACCACGAAGACAACAAGACCTAAGGACAAGGCCTCCA
 [H K L P V R L L V L L L F W I P V S G G]
 Signal Peptide

61 GATGTTGTGGTGAAGTCAAACTCCACTCTCCCTGCCCTGTCAGCTTTGGAGATCAAGTTTCT 120
 CTACAACACCACTGAGTTTGAGGTGAGAGGGACGGACAGTCGAAACCTCTAGTTCAAAGA
 [D V V V T Q T P L S L P V S F G D Q V S]
 Framework 1

121 ATCTCTGCCAGGTCTAGTCAGAGTCTTGCAAAGAGTTATGGGAACACCTATTGTCTTGG 180
 TAGAGAACGTCCAGATCAGTCTCAGAACGTTTCTCAATACCCTTGTGGATAAACAGAACC
 I S C][R S S Q S L A K S Y G N T Y L S][W
 CDR 1

181 TACCTGCACAAGCCTGGCCAGTCTCCACAGCTCCTCATCTATGGGATTTCACACAGATT 240
 ATGGACGTGTTCCGACCGGTGAGAGGTGTCGAGGAGTAGATACCCTAAAGGTTGTCTAAA
 Y L H K P G Q S P Q L L I Y][G I S N R F
 CDR 2
 Framework 2

241 TCTGGGGTGCCAGACAGGTTGAGTGGCAGTGGTTCAGGGACAGATTTCACACTCAAGATC 300
 AGACCCACGGTCTGTCCAAGTCACCGTCACCAAGTCCCTGTCTAAAGTGTGAGTTCTAG
 S][G V P D R F S G S G S G T D F T L K I
 Framework 3

301 AGCACAATAAGCCTGAGGACTTGGGAATGTATTACTGCTTACAAGGTACACATCAGCCG 360
 TCGTGTTATTTCCGACTCCTGAACCCCTTACATAATGACGAATGTTCCATGTGTAGTCGGC
 S T I K P E D L G M Y Y C][L Q G T H Q P
 CDR3

361 TACACGTTCCGAGGGGGGACCAAGCTGGAAATAAAA 396
 ATGTGCAAGCCTCCCCCTGGTTCGACCTTTATTTT
 Y T][F G G G T K L E I K]
 Framework 4

FIGURE 7

1 GATATTGTGATGACTCAGTCTCCACTCTCCCTGCCCGTCACCCCTGGAGAGCGGGCTCC 60
 CTATAACACTACTGAGTCAGAGGTGAGAGGGACGGGCAGTGGGGACCTCTCGGCCGGAGG
 [D I V H T Q S P L S L P V T P G E P A S

Framework 1

61 ATCTCCTGCAGGTCTAGTCAGAGCCTCCTCCATAGTAATGGATCAAACCTATTGGATTGG 120
 TAGAGGACGTCCAGATCAGTCTCGGAGGAGGTATCATTACCTAGTTTGATAAACCTAACCC
 I S C][R S S Q S L L H S N G Y N Y L D][W

CDR 1

121 TACCTGCAGAAGCCAGGGCAGTCTCCACAGCTCCTGATCTATTGGGTTCTAATCGGGCC 180
 ATGGACGTCTTCGGTCCCGTCAGAGGTGTCGAGGACTAGATAAACCCCAAGATTAGCCCGG
 Y L Q K P G Q S P Q L L I Y][L G S N R A

Framework 2

CDR 2

181 TCCGGGGTCCCTGACAGGTTCA GTGGCAGTGGATCAGGCACAGATTTTACTGAAAATC 240
 AGGCCCCAGGGACTGTCCAAGTCACCGTCACCTAGTCCGTGTCTAAAATGTGTCTTTTAG
 S][G V P D R F S G S G S G T D F T L K I

Framework 3

241 AGCAGAGTGGAGGCTGAGGATGTTGGGGTTTATTACTGCATGCAAGCTCTACCAACTCCT 300
 TCGTCTCACCTCCGACTCCTACAACCCCAAATAATGACGTACGTTGAGATGGTTGAGGA
 S R V E A E D V G V Y Y C][M Q A L Q T P

CDR 3

301 CAGACGTTCCGGCCAAGGGACCAAGGTGGAAATCAA 336
 GTCGTCAAGCCGGTTCCTGGTTCACCTTTAGTTT
 Q T][F G Q G T K V E I K]

Framework 4

FIGURE 8

1 ATGGGATGGAGCTGTATCATCCTCTTCTTGGTATCAACAGCTACAAGTGTCCACTCCCAG 60
 TACCCTACCTCGACATAGTAGGAGAAGAACCATAGTTGTGCGATGTTACAGGTGAGGGTC
 M G W S C I I L F L V S T A T S V H S] [Q

Signal Peptide

61 GTCCAAGTGCAGCAGCCTGGGGCTGAGCTTGTGAAGCCTGGGACTTCAGTGAAGCTGTCC 120
 CAGGTTGACGTGCTCGGACCCGACTCGAACACTTCGGACCTGAAGTCACTTCGACAGG
 V Q L Q Q P G A E L V K P G T S V K L S

Framework 1

121 TGCAAGGGTTATGGCTACACCTTCACCAGCTACTGGATGCACTGGGTGAAGCAGAGGCCCT 180
 ACGTTCCCAATACCGATGTGGAAGTGGTGGATGACCTACGTGACCCACTTCGTCTCCGGA
 C K G Y G Y T F T] [S Y W M H] [W V K Q R P

CDR 1

181 GGACAAGGCCTTGAGTGGATCGGAGAGATTGATCCTTCTGAGAGTAATACTAACTACAAT 240
 CCTGTTCCGGAACCTCACCTAGCCTCTCTAACTAGGAAGACTCTCATTATGATTGATGTTA
 G Q G L E W I G] [E I D P S E S N T N Y N

CDR 2

Framework 2

241 CAAAAATTCAAGGGCAAGGCCACATTGACTGTAGACATTTCTCCAGCACAGCCTACATG 300
 GTTTTAAAGTTCCCGTTCGGGTGTAAGTACATCTGTAAAGGAGGTCGTGTCGGATGTAC
 Q K F K G] [K A T L T V D I S S S T A Y M

Framework 3

301 CAGCTCAGCAGCCTGACATCTGAGGACTCTGCGGTCTACTATTGTGCAAGAGGGGGTTAC 360
 GTCGAGTGTGCGGACTGTAGACTCCTGAGACGCCAGATGATAACAGTTCTCCCCCAATG
 Q L S S L T S E D S A V Y Y C A R] [G G Y

361 GACGGATGGGACTATGCTATTGACTACTGGGGTCAAGGCACCTCAGTCACCGTCTCCTCA 420
 CTGCCTACCCTGATACGATAACTGATGACCCAGTTCCGTGGAGTCAGTGGCAGAGGAGT
 D G W D Y A I D Y] [W G Q G T S V T V S S]

Framework 4

CDR 3

FIGURE 9

1 ATGGAGTTTGGGCTGAGCTGGCTTTTCTTGTGGCTATTTTAAAAGGTGTCCAGTGTCTAG 60
 TACCTCAAACCGACTCGACCGAAAAAGAACACCGATAAAATTTCCACAGGTCACAGTC
 [M E F G L S W L F L V A I L K G V Q C][Q

Signal peptide

61 GTGCAGCTTGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTTTCC 120
 CACGTCGAACACGTCAGACCCGACTCCACTTCTTCGGACCCCGGAGTCACTTCCAAAGG
 V Q L V Q S G A E V K K P G A S V K V S

Framework 1

121 TGCAAGGCTTCTGGATACACCTTCACTAGCTATGCTATGCATTGGGTGCGCCAGGCCCC 180
 ACGTTCGGAAGACCTATGTGAAGTGATCGATACGATACGTAACCCACGCGGTCCGGGGG
 C K A S G Y T F T][S Y A M H][W V R Q A P

CDR 1

181 GGACAAAGGCTTGAGTGGATGGGATGGATCAACGCTGGCAATGGTAACACAAAATATTCA 240
 CCTGTTTCCGAACCTACCTACCCTACCTAGTTGCGACCGTTACCATTGTGTTTATAAGT
 G Q R L E W M G][W I N A G N G N T K Y S

Framework 2

CDR 2

241 CAGAAGTTCAGGGCAGAGTCACCATTACCAGGGACACATCCGCGAGCACAGCCTACATG 300
 GTCTTCAAGTCCCGTCTCAGTGGTAATGGTCCCTGTGTAGGCGCTCGTGTGGATGTAC
 Q K F Q G][R V T I T R D T S A S T A Y M

301 GAGCTGAGCAGCCTGAGATCTGAAGACACGGCTGTGTATTACTGTGCGAGAGGAGGTTAC 360
 CTCGACTCGTCCGACTCTAGACTTCTGTGCCGACACATAATGACACGCTCTCCTCCAATG
 E L S S L R S E D T A V Y Y C A R][G G Y

Framework 3

361 TATGGTTCGGGGAGCAACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCA 414
 ATACCAAGCCCCTCGTTGATGACCCCGGTCCCTTGGGACCAAGTGGCAGAGGAGT
 Y G S G S N Y][W G Q G T L V T V S S]

CDR 3

Framework 4

FIGURE 10

Sequence Range: 1 to 540

10 20 30 40
 ATG AAA TGC ACC TGG GTC ATT CTC TTC TTG GTA TCA ACA GCT ACA AGT
 M K C T W V I L F L V S T A T S>
 50 60 70 80 90
 GTC CAC TCG CAG GTC CAA CTA GTG CAG TCT GGG GCT GAG GTT AAG AAG
 V H S Q V L V Q S G A E V K K>
 100 110 120 130 140
 CCT GGG GCT TCA GTG AAG GTG TCC TGC AAG GGT TCT GGC TAC ACC TTC
 P G A S V K V S C K G S G Y T F>
 150 160 170 180 190
 ACC AGC TAC TGG ATG CAT TGG GTG AGG CAG GCG CCT GGC CAA CGT CTA
 T S Y W M H W V R Q A P G Q R L>
 200 210 220 230 240
 GAG TGG ATC GGA GAG ATT GAT CCT TCT GAG AGT AAT ACT AAC TAC AAT
 E W I G E I D P S E S N T N Y N>
 250 260 270 280
 CAA AAA TTC AAG GGA CGC GTC ACA TTG ACT GTA GAC ATT TCC GCT AGC
 Q K F K G R V T L T V D I S A S>
 290 300 310 320 330
 ACA GCC TAC ATG GAG CTC AGC AGC CTG AGA TCT GAG GAC ACT GCG GTC
 T A Y M E L S S L R S E D T A V>
 340 350 360 370 380
 TAC TAT TGT GCA AGA GGG GGT TAC GAC GGA TGG GAC TAT GCT ATT GAC
 Y Y C A R G G Y D G W D Y A I D>
 390 400 410 420 430
 TAC TGG GGT CAA GGC ACC CTG GTC ACC GTC TCC TCA GCC TCC ACC AAG
 Y W G Q G T L V T V S S A S T K>
 440 450 460 470 480
 GGC CCA TCG GTC TTC CCC CTG GCA CCC TCC TCC AAG AGC ACC TCT GGG
 G P S V F P L A P S S K S T S G>
 490 500 510 520
 GGC ACA GCG GCC CTG GGC TGC CTG GTC AAG GAC TAC TTC CCC GAA CCG
 G T A A L G C L V K D Y F P E P>
 530 540
 GTG ACG GTG TCG
 V T V S>

Signal peptide cleavage site
Start
Ala
Const region
BS410

FIGURE 11

Sequence Range: 1 to 413

10 20 30 40
 * * * *
 ATG AAG TTG CCT GTT AGG CTG TTG GTG CTT CTG TTG TTC TGG ATT CCT
 M K L P V R L L V L L L F W I P>
 50 60 70 80 90
 * * * * *
 GTT TCC GGA GGT GAT GTT GTG ATG ACT CAA AGT CCA CTC TCC CTG CCT
 V S G G D V V M T Q S P L S L P>
 100 110 120 130 140
 * * * * *
 GTC ACC CCT GGA GAA CCA GCT TCT ATC TCT TGC AGG TCT AGT CAG AGT
 V T P G E P A S I S C R S S Q S>
 150 160 170 180 190
 * * * * *
 CTT GCA AAG AGT TAT GGG AAC ACC TAT TTG TCT TGG TAC CTG CAG AAG
 L A K S Y G N T Y L S W Y L Q K>
 200 210 220 230 240
 * * * * *
 CCT GGC CAG TCT CCA CAG CTC CTC ATC TAT GGG ATT TCC AAC AGA TTT
 P G Q S P Q L L I Y G I S N R F>
 250 260 270 280
 * * * * *
 TCT GGG GTG CCA GAC AGG TTC AGT GGC AGT GGT TCA GGG ACA GAT TTC
 S G V P D R F S G S G S G T D F>
 290 300 310 320 330
 * * * * *
 ACA CTC AAG ATC TCG CGA GTA GAG GCT GAG GAC GTG GGA GTG TAT TAC
 T L K I S R V E A E D V G V Y Y>
 340 350 360 370 380
 * * * * *
 TGC TTA CAA GGT ACA CAT CAG CCG TAC ACG TTC GGA CAG GGG ACC AAG
 C L Q G T H Q P Y T F G Q G T K>
 390 400 410
 * * *
 GTG GAA ATA AAA CGG GCT GAT GCG GCG CC
 V E I K R A D A A P>

Signal peptide cleavage site
Base 1
MSI
Asp 718
MSI
MSI
410 kact

FIGURE 12

LIGHT CHAIN OLIGOS.

08/700737

DOUBLE STRAND
FRAGMENTS

- L1 5'- TTT CCG GAG GTG ATG TTG TGA TGA CTC AAA GTC CAC TCT CCC
TGC CTG TCA CCC CTG GAG AAC CAG CTT CTA TCT CTT GCA
GGT CTA GTC AGA G
- L2 5'- ACT GGC CAG GCT TCT GCA GGT ACC AAG ACA AAT AGG TGT TCC
CAT AAC TCT TTG CAA GAC TCT GAC TAG ACC TGC AAG AGA
TAG AAG CTG GTT C
- L3 5'- CCT GGC CAG TCT CCA CAG CTC CTC ATC TAT GGG ATT TCC AAC
AGA TTT TCT GGG GTG CCA GAC AGG TTC AGT GGC AGT GGT
TC
- L4 5'- ACT CGC GAG ATC TTG AGT GTG AAA TCT GTC CCT GAA CCA CTG
CCA CTG AAC CTG TCT GGC ACC CCA GAA AAT CTG TTG GAA
ATC
- L5 5'- TCT CGC GAG TAG AGG CTG AGG ACG TGG GAG TGT ATT ACT GCT
TAC AAG GTA CAC ATC AGC CGT ACA C
- L6 5'- ATG GCG CCG CAT CAG CCC GTT TTA TTT CCA CCT TGG TCC CCT
GTC CGA ACG TGT ACG GCT GAT GTG TAC CTT GTA AGC AGT
AAT AC

LA

LB

LC

HEAVY CHAIN OLIGOS

DOUBLE STRAND
FRAGMENT

- H1 5'- ATA AGC TTC GCC ATG AAA TGC ACC TGG GTC ATT CTC TTC TTG
GTA TCA ACA GCT ACA AGT GTC CAC TCC CAG GTC CAA CTA
GTG CAC CGG TTA
- H2 5'- TAA CCG GTG CAC TAG TTG GAC CTG GGA GTG GAC ACT TGT AGC
TGT TGA TAC CAA GAA GAG AAT GAC CCA GGT GCA TTT CAT
GGC GAA GCT TAT
- H3 5'- CAA CTA GTG CAG TCT GGG GCT GAG GTT AAG AAG CCT GGG GCT
TCA GTG AAG GTG TCC TGC AAG GGT TCT GGC TAC ACC TTC
ACC AGC
- H4 5'- TAA CCG GTA CTC TAG ACG TTG GCC AGG CGC CTG CCT CAC CCA
ATG CAT CCA GTA GCT GGT GAA GGT GTA GCC AGA ACC CTT
GCA GGA C
- H5 5'- CGT CTA GAG TGG ATC GGA GAG ATT GAT CCT TCT GAG AGT AAT
ACT AAC TAC AAT CAA AAA TTC AAG GGA CGC GTC A
- H6 5'- TAA CCG GTG TGC TAG CGG AAA TGT CTA CAG TCA ATG TGA CGC
GTC CCT TGA ATT TTT GAT TGT AGT TAG TAT TAC T
- H7 5'- CCG CTA GCA CAG CCT ACA TGG AGC TCA GCA GCC TGA GAT CTG
AGG ACA CTG CGG TCT ACT ATT GTG CAA GAG GGG GTT ACG
ACG GAT G
- H8 5'- TCA CCG GTG CGG TGA CCA GGG TGC CTT GAC CCC AGT AGT CAA
TAG CAT AGT CCC ATC CGT CGT AAC CCC CTC TTG CAC AAT
AGT AGA C
- H9 5'- CTG GTC ACC GTC TCC TCA GCC TCC ACC AAG GGC CCA TCG GTC
TTC CCC CTG GCA CCC TCC TCC AAG AGC ACC TCT GGG GGC
ACA G
- H10 5'- TCA CCG GTT CGG GGA AGT AGT CCT TGA CCA GGC AGC CCA
GGG CCG CTG TGC CCC CAG AGG TGC TCT TGG AGG AGG GTG
CCA GGG G

HA

HB

HC

HD

HE

FIGURE 13




FIGURE 14




FIGURE 15




FIGURE 16

LDP-02 DOES NOT PARTICIPATE IN COMPLEMENT MEDIATED CELL LYSIS




FIGURE 17

—●— Murine ACT-1 Lot #5.1
—■— Murine IgG1

ADHESION ASSAY




FIGURE 18A

● LDP-02/3A9/Lot#1A
■ Hs IgG1

ADHESION ASSAY




FIGURE 18B




FIGURE 19